Prudence Kgagudi to Spike Glycoprotein, Coronavirus
This is a "connection" page, showing publications Prudence Kgagudi has written about Spike Glycoprotein, Coronavirus.
Connection Strength
0,812
-
Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination. Front Immunol. 2023; 14:1231276.
Score: 0,206
-
Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants. J Virol. 2022 08 10; 96(15):e0055822.
Score: 0,191
-
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021 Aug 13; 373(6556).
Score: 0,178
-
A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories. Viruses. 2024 12 18; 16(12).
Score: 0,057
-
Emergence and phenotypic characterization of the global SARS-CoV-2 C.1.2 lineage. Nat Commun. 2022 04 08; 13(1):1976.
Score: 0,047
-
Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. Sci Transl Med. 2022 Feb 09; 14(631):eabj6824.
Score: 0,046
-
Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). N Engl J Med. 2021 06 03; 384(22):2161-2163.
Score: 0,044
-
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021 04; 27(4):622-625.
Score: 0,044